Zantac Trial Schedule
Updated December 3, 2024
Wisner Baum has helped negotiate several Zantac lawsuit settlements:
- In October of 2024, GSK agreed to pay up to $2.2 billion to settle approximately 80,000 cases, which represents about 93% of the Zantac lawsuits pending against the company in U.S. state courts
- In May of 2024, Pfizer reached agreements to settle more than 10,000 Zantac lawsuits.
- In April of 2024, Sanofi agreed to settle roughly 4,000 Zantac cases in state courts outside of Delaware.
The makers of Zantac (ranitidine) are facing lawsuits in several state courts alleging the widely-used heartburn medication causes several types of cancer. Approximately 80,000 Zantac lawsuits are pending in the following state courts:
- California
- Connecticut
- Delaware
- Illinois
- Pennsylvania
ZANTAC TRIAL UPDATE – CALIFORNIA STATE COURT
November 21, 2024: Russell v. Boehringer Ingelheim ended with a hung jury. The jury agreed that Zantac was dangerous and that Boehringer Ingelheim failed to warn consumers about the drug's risks. However, the jury was split 6-6 on whether Zantac directly caused Mr. Russell's cancer, which means they could not reach a verdict. Russell's attorneys, R. Brent Wisner and Jennifer Moore, told the media they, “stand ready to retry this case immediately,” adding that, “Boehringer dodged a bullet today - that won't happen again.”
November 6, 2024: The jury is now deliberating in Russell v. Boehringer Ingelheim Pharmaceuticals, Inc. We will update this page once a verdict has been reached.
October 28, 2024: Wisner Baum and co-counsel rested our case in Russell v. Boehringer Ingelheim Pharmaceuticals, Inc. The trial will likely continue until mid to late November.
October 3, 2024: The jury in Russell v. Boehringer Ingelheim was finalized yesterday. Today, we begin opening statements.
September 30, 2024: Jury selection begins today in the case of Russell v. Boehringer Ingelheim.
September 27, 2024: Judge Noël Wise denied Boehringer’s motion to dismiss plaintiff John Wayne Russell’s claim for punitive damages. Mr. Russell’s case is the first Zantac trial against Boehringer where punitive damages will be at stake.
Jury selection begins Monday, September 30, in Alameda County Superior Court.
September 23, 2024: Trial is set to begin in California for plaintiff John Wayne Russell. Mr. Russell alleges Zantac causes bladder cancer. Our law firm and co-counsel negotiated a settlement with GSK on Mr. Russell’s behalf. However, we are still preparing for trial against defendant Boehringer Ingelheim.
June 10, 2024: A tentative trial date for the first case in the California Zantac JCCP has been set for September 30, 2024. The case will be tried by R. Brent Wisner, managing partner of Wisner Baum, and Jennifer Moore of the Moore Law Group. The two Zantac lawyers have successfully settled several claims ahead of trial this year. The trial will take place in Alameda, California.
March 6, 2024: Both parties and the court are finalizing the trial dates for the next round of Zantac trials in California. We will update this page when new information is available. Our firm and the Moore Law Group have secured several Zantac settlements over the last few months for plaintiffs before trials were scheduled to begin.
ZANTAC TRIAL UPDATE – CONNECTICUT STATE COURT
August 23, 2024: A Connecticut state court judge has denied motions to dismiss filed by pharmaceutical companies in consolidated Zantac lawsuits, allowing the litigation to proceed. The defendants, including Boehringer Ingelheim, GlaxoSmithKline, Pfizer, and Sanofi, had challenged the court's jurisdiction over claims alleging that Zantac causes cancer. But the court asserted jurisdiction based on the companies' substantial business activities in Connecticut and their consent to jurisdiction by registering to do business in the state. The judge also rejected drug manufacturer defendant arguments against "innovator liability" and claims based on specific dates of use and manufacturing.
ZANTAC TRIAL UPDATE – DELAWARE STATE COURT
June 1, 2024: Judge Vivian Medinilla's ruling today allows over 70,000 Zantac cancer lawsuits to proceed. The judge ruled that expert witnesses can testify in court regarding the potential cancer risks associated with Zantac (ranitidine), which brings cases filed in Delaware one step closer to getting the science alleged in lawsuits before a jury.
You can read Judge Medinilla’s order here.
March 4, 2024: As of today, there are over 72,000 filed Zantac cases in Delaware State Court, which accounts for the vast majority of Zantac lawsuits that have been filed across the country.
The court recently heard arguments in Daubert. This is the test for admissibility of expert witness testimony. The Judge will decide if experts are qualified to opine on issues related to these cases, including any causal connections between Zantac/ranitidine and the various cancers. This is a crucial test that will largely determine if the court will proceed with claims related to some or all of the various cancers.
The process for selecting the first cases for trial is also underway. This is known as the bellwether selection process. We expect more developments after the Judge rules on Daubert.
January 25, 2024: The hearings on Daubert before the Hon. Judge Vivian L. Medinilla concluded today. What is a Daubert hearing? It is when legal teams for both sides present their experts to educate the court on the science underpinning their arguments.
The plaintiffs must demonstrate that they have scientific evidence to support their allegations, and that they used recognized, reliable methodology for arriving at their scientific opinions. If the judge determines those methodologies are valid, expert witnesses will be allowed to testify and the Zantac cancer cases in Delaware can proceed to trial.
ZANTAC TRIAL UPDATE – ILLINOIS STATE COURT
September 18, 2024: Another mistrial was declared in an Illinois lawsuit against Boehringer Ingelheim, alleging the company’s heartburn medication Zantac caused plaintiff Ronald Kimbrow’s prostate cancer. The latest mistrial in Illinois follows a similar deadlock in August involving plaintiff Martin Gross, who also sued Boehringer Ingelheim over Zantac.
August 7, 2024: An Illinois judge declared a mistrial in a lawsuit claiming that Boehringer Ingelheim’s over-the-counter Zantac caused a man to develop prostate cancer. The jury could not reach a unanimous verdict. The parties will return to Cook County's chief judge next week to set a new trial date, and possibly assign a new judge.
August 5, 2024: GSK announced today that a Zantac trial in Illinois has ended with a jury finding that ranitidine did not cause a plaintiff’s colorectal cancer.
July 29, 2024: The case of Kimbrow v. GlaxoSmithKline has culminated in a confidential settlement. The plaintiff alleged Zantac caused prostate cancer.
June 10, 2024: GSK stated the Illinois Zantac trial that was supposed to start today was voluntarily dismissed by the plaintiff.
June 2, 2024: Several Zantac trials are scheduled for Illinois in June, July, September, and November of 2024.
ZANTAC TRIAL UPDATE – PENNSYLVANIA STATE COURT
June 3, 2024: A Zantac trial in Philadelphia has been scheduled for February 2025.
If you were diagnosed with cancer after taking Zantac, you may be eligible to pursue compensation in a Zantac lawsuit. To learn more about your legal rights, please call (855) 948-5098 or fill out our contact form to start the free case evaluation process.
Wisner Baum's Blog
Recent Posts
Our Case Results
-
$10 Million Settlement Celexa-Lexapro Pediatric Class Action
$10 million pediatric class action re false promotion of Celexa and Lexapro. Babies born to women who have used Lexapro and other similar medications such as Zoloft, Celexa, Prozac, Paxil, and Symbyax are at an increased risk for birth defects.
-
$28 Million Settlement Defective Drug Class Action
$28 million Paxil defective drug class action. A class action has been brought in the US territory of Puerto Rico against UK-based drug major GlaxoSmithKline.
-
$9 Million Settlement Drug Injury
Wisner Baum obtained a $9 million settlement on behalf of an individual who was injured by a drug.
-
$63 Million Settlement Paxil Pediatric Class Action
$63 million pediatric class action re false promotion of Paxil. Judge approves final terms of improved national pediatric paxil class action settlement – consumers get a better deal.
-
$105 Million Settlement Pharmaceutical Settlement
Wisner Baum obtained $105 million on behalf of multiple clients involved in a pharmaceutical negligence case.
-
$40 Million Settlement Third-Party Payer Class Action
$40 million third-party payer class action re off-label promotion of Paxil. Judge approves $40 million settlement in the second phase of national pediatric paxil class action – insurance companies to be reimbursed.
Client-Focused Representation
REVIEWS & TESTIMONIALS
We believe our track record speaks for itself. But you don’t have to take our word for it. See what our clients have to say about working with us.
-
"I Can’t Imagine a Better Law Firm"
Multiple lawyers recommended Wisner Baum to me and I have been consistently impressed with the quality of their work.
- Best Law Firms Survey -
"They Are About Changing the Systems..."
Wisner Baum are not only amazing attorneys but more importantly, they are activists. They are about changing the systems which got us into trouble in the first place. They understand their role in the process of making change.
- Kim Witczak -
"Top Legal Minds in the Country"
The Wisner Baum firm has some of the top legal minds in the country; they are driven, determined, trustworthy, ethical and passionate.
- From Best Lawyers® Best Law Firms
